Share This Author
Prognostic score including gene mutations in chronic myelomonocytic leukemia.
A new prognostic score based on mutational status, age, hemoglobin, WBC, and platelet counts defines three groups of CMML patients with distinct outcomes that appear more discriminative than those based solely on clinical parameters.
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
A 17-gene stemness score for rapid determination of risk in acute leukaemia
The LSC17 score provides clinicians with a rapid and powerful tool to identify AML patients who do not benefit from standard therapy and who should be enrolled in trials evaluating novel upfront or post-remission strategies.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRd in clinical practice.
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
- D. Cilloni, Aline Renneville, D. Grimwade
- Medicine, BiologyJournal of clinical oncology : official journal…
- 1 November 2009
Application of a standardized WT1 assay provides independent prognostic information in AML, lending support to incorporation of early assessment of MRD to develop more robust risk scores, to enhance risk stratification, and to identify patients who may benefit from allogeneic transplantation.
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
Results indicate that TET2 mutations observed in approximately 20% of patients, irrespective of the World Health Organization or French-American-British subtype, represent a molecular marker for good prognosis in MDS.
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
It is demonstrated that splice gene mutations are among the most frequent molecular aberrations in myelodysplastic syndrome, define distinct clinical phenotypes, and show preferential associations with mutations targeting transcriptional regulation.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
- C. Preudhomme, J. Guilhot, F. Guilhot
- Medicine, BiologyNew England Journal of Medicine
- 22 December 2010
As compared with other treatments, the addition of peginterferon alfa-2a to imatinib therapy resulted in significantly higher rates of molecular response in patients with chronic-phase CML.
Clonal architecture of chronic myelomonocytic leukemias.
Comparison of clonal expansions of TET2 mutations in MDS, MPN, and CMML, together with functional invalidation of Tet2 in sorted progenitors, suggests a causative link between early clonal dominance and skewed granulomonocytic differentiation.
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
A risk classification is proposed that includes in the favorable subgroup all patients from the intermediate subgroup displaying CEBPA mutations when not associated with FLT3-ITD, and appears to act as a major bad prognosis factor in patients withCEBPA-mutated AML.